With the launch of Project Optimus, the FDA is reforming the dose optimization and dose selection paradigm in oncology drug development. Why? Poorly characterized dose and schedule may lead to selection of a dose that provides more toxicity without additional efficacy.

What does this mean for drug developers? Drug developers may have to:

  • Redirect early clinical development objectives
  • Re-think recommended Phase 2 dose justifications
  • Understand and manage immunogenicity of biologics
  • Assess impact on time and cost
  • Navigate uncertain regulatory landscape and expectations

With deep experience in model-informed oncology drug development, dosing and regulatory strategy and submission, Certara has helped to advance hundreds of oncology programs. Our proven, integrated approach using quantitative methods can help you to navigate this regulatory change. The key lesson is to start early, including engaging with the FDA sooner than later.


Solutions to Help You Prepare for Optimus

Get the dose right the first time

Getting your dosing strategy right is now even more imperative with Project Optimus. How do we improve therapeutic response and lower the risk of toxicity for cancer patients? We believe that the best way to determine and refine your dosing strategy is through model-informed drug development. Our quantitative, model-informed approaches have helped to predict drug exposure and response, determine first-in-human dosing and optimize trial design, advancing hundreds of oncology programs.

  • Dose finding using quantitative methods, such as Simcyp PBPK modeling and simulation or population PK analysis
  • Clinical pharmacology gap analysis
  • Early development, IND-enabling support
Free consultation
Get the dose right the first time
Navigate the changing regulatory landscape

Navigate the changing regulatory landscape

It is essential to engage early with the FDA in this evolving environment. How? Our integrated team of regulatory experts provides regulatory strategy, consulting and submissions support to advance your program.

Regulatory Strategy: Increase your oncology product’s chance of approval with guidance from our seasoned regulatory experts specializing in regulatory intelligence, policy and strategy. With Project Optimus, the integration of model-informed drug development and regulatory strategy early on in development is critical to your success.

Regulatory Submissions: Without careful planning, anticipation of risks, expert execution and ability to navigate unexpected challenges, your oncology submission may fall off track. Rely on our around-the-clock support, expert team and advanced regulatory technology to support you every step of the way.

  • Accelerated, Fast-track, PRIME and Breakthrough Therapy Designations
  • Global and parallel submission preparation and leadership
  • Regulatory writing powered by technology to increase consistency, quality and speed

Get the Simcyp Advantage

What is the Simcyp Simulator? The Simcyp Simulator is the pharmaceutical industry’s most sophisticated physiologically based pharmacokinetic (PBPK) platform for determining first-in-human dosing, optimizing clinical study design, evaluating new drug formulations, setting the dose in untested populations, and predicting drug-drug interactions. The Simcyp Simulator has been used to help inform more than 30 novel oncology drug approvals by the FDA. Using quantitative systems pharmacology, our IO and IG Simulators are state-of-the-art technology that help to inform critical decisions in oncology drug development.

Immuno-oncology Simulator: Our IO Simulator incorporates compounds’ pharmacokinetics, target binding, and mechanisms of action as well as existing knowledge on the underlying tumor and immune system biology to predict clinical results for novel combinations and complex biologics such as bi-specifics.

Immunogenicity Simulator: Our IG Simulator, adopted by the FDA and developed in partnership with 8 leading pharmaceutical companies, predicts immunogenicity incidence of therapeutics in development and potential impacts on pharmacokinetics and pharmacodynamics.

Get the Simcyp Advantage
IND-enabling regulatory and drug development

IND-enabling regulatory and drug development

The early drug development process is complex, and with Project Optimus, it is critical to work with an experienced team to deliver a robust first-in human (FIH)-enabling study design and regulatory strategy and meeting support. Our oncology experts support the full range of early development disciplines (ADME, bioanalytical, toxicology and drug safety, and CMC) for small and large molecules.

How are we different? Our deep expertise and quantitative approaches inform your most critical decisions with confidence. Since 2019, Certara’s services supported our clients as they have raised more than $65 billion in funding from venture capital and acquisitions

Get peace of mind now. Benefit from complete ADME packages as well as an optimized GLP toxicology/safety pharmacology and regulatory program tailored for Project Optimus to advance your IND.

FIH Strategies

Modeling and simulation for oncology dose evaluation

Modeling and simulation (M&S) approaches can improve dose selection and provide a risk-benefit assessment when developing an oncology drug. Considerations and analyses such as:

  • PK sampling
  • PK/PD relationships
  • Exposure-response analyses
  • Body weight-based dosing, and
  • Food effect

help ensure the right dose is administered at the right time to the right patient.

Modeling and simulation for oncology dose evaluation
Bio Pic JulieBullock
Julie Bullock, PharmD Vice President, Global Head of Clinical Pharmacology & Translational Medicine

米国 FDA において 10 年以上医薬品承認申請の審査に携わり、14 件以上の新薬の承認に貢献してきました。小児用医薬品の開発、生物学的製剤の PK/PD 解析および開発アプローチ、抗がん剤の投与戦略、画期的治療薬の開発、および迅速承認に関して深い見識を持っています。

Bio Pic PietGraaf
Piet van der Graaf, PharmD, PhD Senior Vice President, Quantitative Systems Pharmacology

製薬業界 (Sanofi および Pfizer) において20 年以上の経験があります。QSP プロジェクトに重要な技術と経験をもたらし、サターラの戦略的な開発に貢献しています。また、CPT の Editor-in-Chief でもあります。

Steve Sibley
Steve Sibley Vice President, Synchrogenix Regulatory Science

医薬品業界での 30 年余にわたるキャリアを持つ、Steve は、レギュラトリーライティング、コンサルティング、プロジェクトリーダーシップの職務において、豊富な経験を有しています。彼は創薬から薬事承認まで、またライフサイクル管理において、多くのプロジェクトの成功を支えてきました。具体的には、75 件以上の薬事申請において重要な役割に就き、いくつかの事例では薬事申請チーム全体を指揮し、モジュール 1 から 5 までのすべての書類作成、文書公開、規制当局への送信を監督してきました。

Powered by Translations.com GlobalLink OneLink Software